COPD Exacerbation

Respiratory
0
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Monaghan Medical
Monaghan MedicalNY - Plattsburgh
1 program
BANN/A1 trial
Active Trials
NCT03985748UnknownEst. Jul 2021
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Comparative Effectiveness of Symbicort vs. Spiriva Among COPD PatientsN/A1 trial
Active Trials
NCT01917643Completed2,396Est. Nov 2013
Verona Pharma
Verona PharmaUK - London
1 program
HIRTN/A1 trial
Active Trials
NCT07302425RecruitingEst. May 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Verona PharmaHIRT
Monaghan MedicalBAN
AstraZenecaComparative Effectiveness of Symbicort vs. Spiriva Among COPD Patients

Clinical Trials (3)

Total enrollment: 2,396 patients across 3 trials

High-intensity Resistance Training in Post-exacerbation COPD

Start: Oct 2025Est. completion: May 2028
N/ARecruiting

Breath-actuated Nebulizers in Acute COPD Exacerbations

Start: Oct 2019Est. completion: Jul 2021
N/AUnknown
NCT01917643AstraZenecaComparative Effectiveness of Symbicort vs. Spiriva Among COPD Patients

Comparative Effectiveness of Symbicort vs. Spiriva Among COPD Patients

Start: Aug 2013Est. completion: Nov 20132,396 patients
N/ACompleted

Related Jobs in Respiratory

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 2,396 patients
3 companies competing in this space